Brain injuries remain one of the most devastating and under-treated global health challenges. TEQCool AB is now taking bold, regulation-aligned steps to bring its groundbreaking non-invasive brain cooling system to clinics—and to the patients who urgently need it.

“Our mission is simple: prevent secondary brain damage before it occurs. Our method is disruptive: rapid, focal brain cooling without the need for sedation or systemic hypothermia. The future of neuroprotection starts here,” says Anders Sjögren, CEO of TEQCool.

Clinical Trials Ahead – A Critical Step Toward the Market
Following strong preclinical results, TEQCool is preparing to launch its first clinical trials in the end of 2026, in collaboration with leading neuroclinics in Sweden and across Europe. The initial focus will be on patients suffering from traumatic brain injury and stroke, where the need for rapid neuroprotection is greatest.

The goal is to generate robust clinical data to support CE marking and, in the longer term, regulatory approval in other major markets including the U.S.

Toward the Stock Market – Planned Listing After Summer 2025
As part of its growth strategy, TEQCool plans to go public on a Swedish growth market after the summer of 2025. The listing is intended to secure capital to accelerate regulatory efforts, scale up manufacturing, and prepare for international commercialization.

“We’re entering a pivotal phase. With growing interest from both the healthcare sector and investors, now is the time to take the next step. Going public gives us the resources to realize our vision of making rapid, safe brain cooling a new standard in emergency care,” says Anders Sjögren.

Strategic Partnerships Aligned with Clinical Studies
In parallel with the clinical trials, TEQCool will also initiate collaborations with potential industrial and commercial partners. These partnerships aim to validate the technology in clinical settings and prepare for future distribution and market access.

“The clinical studies are not only medical proof points—they’re also a launchpad for strategic alliances. We see strong interest from medtech companies and healthcare providers who want to be at the forefront of next-generation neuroprotection,” Anders Sjögren concludes.